FDA approves Libervant for seizure clusters in children 2-5; Anaphylm NDA on track for end of 2024

Aquestive Therapeutics, Inc.

Libervant is first FDA-approved oral rescue treatment for seizure clusters in patients ages 2-5.
Immediate availability of 5mg, 7.5mg, 10mg, 12.5mg, and 15mg; non-Medicaid prescriptions being filled.
Over 55,000 prescriptions filled in 2023 for this age group, 90% for diazepam rectal gel.
Anaphylm clinical program on track; NDA submission planned by end of 2024.
This is the Company's 4th FDA approval since 2018.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.